



1625
Ifu

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): CHENG et al.
SERIAL NO.: 10/586,822
FILED: 07/19/2006
FOR: COMPOUNDS AND METHODS TO INCREASE ANTI-P-
GLYCOPROTEIN ACTIVITY OF BAICALEIN BY
ALKYLATION ON THE A RING
INT'L. APPLN. NO.: PCT/US2005/002910
INT'L. FILING DATE: 31 January 2005
GROUP ART UNIT: Not yet available
EXAMINER: Not yet available

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 223313-1450

INFORMATION DISCLOSURE STATEMENT

SIR:

Pursuant to the Duty to Disclose under 37 C.F.R. §1.56(a), applicant encloses herewith a copy of Form PTO-1449 listing documents relevant to the background of the invention described and claimed in the above-identified application. Inclusion of a reference on this list does not necessarily imply that that reference is prior art. For the convenience of the Examiner, copies of the listed non-U.S. patent documents are enclosed.

Applicant respectfully requests that the Examiner consider the enclosed references in determining the patentability of the claimed invention. Applicant also requests that the Examiner return a copy of enclosed Form PTO-1449 with initials or other marks indicating that the references have been so considered. If any fee is due, please charge/credit deposit account no. 04-0838.

Respectfully submitted,

Coleman Sudol Sapone, P.C.

By: 

Henry D. Coleman

Reg. No. 32,559

714 Colorado Avenue

Bridgeport, Connecticut 06605-1601

(203)366-3560

Dated: October 12, 2006



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to: "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" on October 12, 2006.

Harold Hull

Harold Hull

**INFORMATION DISCLOSURE
CITATION IN AN APPLICATION**Att'y Ref:
Y03-097US Nat

Serial No: 10/586,822

Applicant: CHENG, Yung-chi et al.

Filing Date: 07/19/2006

Art Unit:

United States Patent Documents

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date

Foreign Patent Documents

Examiner Initial	Publication Number	Publication Date	Country	Class	Subclass	Translation	
						Yes	No

Examiner Initial	Other Documents (by Title, Author Date, Pertinent Pages, Etc.)
	German, U. A. P-glycoprotein--a mediator of multidrug resistance in tumour cells. <i>Eur J Cancer</i> 1996, 32A, 927-944
	Gottesman, M. M.; Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. <i>Annu Rev Biochem</i> 1993, 62, 385-427

Examiner:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered; Include a copy of this form with next communication to the applicant.

	Thiebaut, F.; Tsuruo, T.; Hamada, H.; Gottesman, M. M.; Pastan, I. et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. <i>Proc Natl Acad Sci USA</i> 1987 , <i>84</i> , 7735-7738
	Borst, P.; Schinkel, A. H. What have we learnt thus far from mice with disrupted P-glycoprotein genes? <i>Eur J Cancer</i> 1996 , <i>32A</i> , 985-990
	Luker, G. D.; Nilsson, K. R.; Covey, D. F.; Piwmica-Worms, D. Multidrug resistance (MDRI) P-glycoprotein enhances esterification of plasma membrane cholesterol. <i>J Biol Chem</i> 1999 , <i>274</i> , 6979-6991
	Dalton, W. S.; Grogan, T. M.; Meltzer, P. S.; Scheper, R. J.; Dude, B. G. et al. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. <i>J Clin Oncol</i> 1989 , <i>7</i> , 415-424
	Miller, T. P.; Grogan, T. M.; Dalton, W. S.; Spier, C. M.; Scheper, R. J. et al. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. <i>J Clin Oncol</i> 1991 , <i>9</i> , 17-24
	Nuessler, V.; Scheulen, M. E.; Oberneder, R.; Kriegmair, M.; Goebel, K. J. et al. Phase I and pharmacokinetic study of the P-glycoprotein modulator dexniguldipine-HCL. <i>Eur J Med Res</i> 1997 , <i>2</i> , 55-61
	Wilson, W. H.; Jamis-Dow, C.; Bryant, G.; Balis, F. M.; Klecker, R. W. et al. Phase I and pharmacokinetic study of the multidrug resistance modulator dexveraparnil with EPOCH chemotherapy. <i>J Clin Oncol</i> 1995 , <i>13</i> , 1985-1994
	Hyafil, F.; Vergely, C.; Du Vignaud, P.; Grand-Perret, T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. <i>Cancer Res</i> 1993 , <i>53</i> , 4595-4602
	Boesch, D.; Gaveriaux, C.; Jachez, B.; Pourtier-Manzanedo, A.; Bollinger, P. et al. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. <i>Cancer Res</i> 1991 , <i>51</i> , 4226-4233
	Ramu, A.; Spanier, R.; Rahamimoff, H.; Fuks, Z. Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells. <i>Br J Cancer</i> 1984 , <i>50</i> , 501-507
	Middleton, E., Jr.; Kandaswami, C.; Theoharides, T. C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. <i>Pharmacol Rev</i> 2000 , <i>52</i> , 673-751
	Bailey, D. G.; Malcolm, J.; Arnold, O.; Spence, J. D. Grapefruit juice-drug interactions. <i>Br J Clin Pharmacol</i> 1998 , <i>46</i> , 101-110
	Ducharme, M. P.; Warbasse, L. H.; Edwards, D. J. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. <i>Clin Pharmacol Ther</i> 1995 , <i>57</i> , 485-491
	De Vincenzo, R.; Scambia, G.; Benedetti Panici, P.; Ranelletti, F. O.; Bonanno, G. et al. Effect of synthetic and naturally occurring chalcones on ovarian cancer cell growth: structure-activity

Examiner:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered; Include a copy of this form with next communication to the applicant.

	relationships. <i>Anticancer Drug Des</i> 1995, 10, 481-490
	Murakami, S.; Muramatsu, M.; Tomisawa, K. Inhibition of gastric H ⁺ , K(+)-ATPase by flavonoids: a structure-activity study. <i>J Enzyme brhib</i> 1999, 14, 151-166
	Akiyama, T.; Ishida, J.; Nakagawa, S.; Ogawara, H.; Watanabe, S. et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. <i>J Biol Chem</i> 1987, 262, 5592-5595
	De Azevedo, W. F., Jr.; Mueller-Dieciemann, H. J.; Schulze-Gahmen, U.; Worland, P. J.; Sausville, E. et al. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. <i>Proc Natl Acad Sci USA</i> 1996, 93, 2735-2740
	Boumendjel, A.; Di Pietro, A.; Dumontet, C.; Barron, D. Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. <i>Med Res Rev</i> 2002, 22, 512-529
	Conseil, G.; Baubichon-Cortay, H.; Dayan, G.; Jault, J. M.; Barron, D. et al. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. <i>Proc Natl Acad Sci USA</i> 1998, 95, 9831-9836
	Perez-Victoria, J. M.; Perez-Victoria, F. J.; Conseil, G.; Maitrejean, M.; Comte, G. et al. High-affinity binding of silybin derivatives to the nucleotide-binding domain of a <i>Leishmania tropica</i> P-glycoprotein-like transporter and chemosensitization of a multidrugresistant parasite to daunomycin. <i>Antimicrob Agents Chemother</i> 2001, 45, 439-446
	Thiyagarajah, P.; Kuttan, S. C.; Lim, S. C.; Teo, T. S.; Das, N. P. Effect of myricetin and other flavonoids on the liver plasma membrane Cat ⁺ pump. Kinetics and structure-function relationships. <i>Biochem Pharmacol</i> 1991, 41, 669-675
	Hirano, T.; Oka, K.; Akiba, M. Effects of synthetic and naturally occurring flavonoids on Na ⁺ ,K ⁺ -ATPase: aspects of the structure-activity relationship and action mechanism. <i>Life Sci</i> 1989, 45, 1111-1117
	Jinsart, W.; Ternai, B.; Polya, G. M. Inhibition of rat liver cyclic AMP-dependent protein kinase by flavonoids. <i>Biol Chem Hoppe Seyler</i> 1992, 373, 205-211
	Ferriola, P. C.; Cody, V.; Middleton, E., Jr. Protein kinase C inhibition by plant flavonoids. Kinetic mechanisms and structure-activity relationships. <i>Biochein Pharmacol</i> 1989, 38, 1617-1624
	Hagiwara, M.; Inoue, S.; Tanaka, T.; Nunoki, K.; Ito, M. et al. Differential effects of flavonoids as inhibitors of tyrosine protein kinases and serine/threonine protein kinases. <i>Biochem Pharmacol</i> 1988, 37, 2987-2992
	Perez-Victoria, J. M.; Chiquero, M. J.; Conseil, G.; Dayan, G.; Di Pietro, A. et al. Correlation between the affinity of flavonoids binding to the cytosolic site of <i>Leishmania tropica</i> multidrug transporter and their efficiency to revert parasite resistance to daunomycin. <i>Biochemistry</i> 1999, 38, 1736-1743
	Lo, A.; Burckart, G. J. P-glycoprotein and drug therapy in organ transplantation. <i>J Clin Pharniacol</i> 1999, 39, 995-1005

Examiner:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered; Include a copy of this form with next communication to the applicant.	

	Wang, R. B.; Kuo, C. L.; Lien, L. L.; Lien, E. J. Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. <i>J Clin Pharm Ther</i> 2003, 28, 203-228
	Di Pietro, A.; Conseil, G.; Perez-Victoria, J. M.; Dayan, G.; Baubichon-Cortay, H. et al. Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. <i>Cell Mol Life Sci</i> 2002, 59, 307-322
	Chambers, T. C.; Pohl, J.; Raynor, R. L.; Kuo, J. F. Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase C. <i>J Biol Chem</i> 1993, 268, 4592-4595
	Callaghan, R.; Higgins, C. F. Interaction of tamoxifen with the multidrug resistance P-glycoprotein. <i>Br J Cancer</i> 1995, 71, 294-299
	Smith, C. D.; Zilfou, J. T. Circumvention of P-glycoprotein-mediated multiple drug resistance by phosphorylation modulators is independent of protein kinases. <i>JBiol Chem</i> 1995, 270, 28145-28152
	Conseil, G.; Perez-Victoria, J. M.; Jault, J. M.; Gamarro, E.; Goffeau, A. et al. Protein kinase C effectors bind to multidrug ABC transporters and inhibit their activity. <i>Biochemistry</i> 2001, 40, 2564-2571
	Dayan, G.; Jault, J. M.; Baubichon-Cortay, H.; Baggetto, L. G.; Renoir, J. M. et al. Binding of steroid modulators to recombinant cytosolic domain from mouse P-glycoprotein in close proximity to the ATP site. <i>Biochemistry</i> 1997, 36, 15208-15215
	Chen, H. X.; Bamberger, U.; Heckel, A.; Guo, X.; Cheng, Y. C. BIBW 22, a dipyridamole analogue, acts as a bifunctional modulator on tumor cells by influencing both P-glycoprotein and nucleoside transport. <i>Cancer Res</i> 1993, 53, 1974-1977
	Park, S. Y.; Lam, W.; Cheng, Y. C. X-ray repair cross-complementing gene 1 protein plays an important role in camptothecin resistance. <i>Cancer Res</i> 2002, 62, 459-465

Examiner:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered; Include a copy of this form with next communication to the applicant.	